Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tradipitant DDI Study with Midazolam
NCT02621385Phase 1Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Nov 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tradipitant in gastroparesis and pruritus, sponsored by Vanda Pharmaceuticals Inc. Primary endpoints: Midazolam Area Under the Curve at 72 hours, Midazolam Time to Maximal Plasma Concentration at 72 hours and 1 more. Started Nov 2015; status: completed.
02
Drugs
tradipitant
03
Conditions
gastroparesispruritus
Beyond the preview
Go deeper on NCT02621385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621385.